Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dapagliflozin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    145 result(s) found for: Dapagliflozin. Displaying page 4 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2007-007540-10 Sponsor Protocol Number: D1690C00006 Start Date*: 2008-03-28
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-week international, randomized, parallel-group, double-blind, placebo-controlled Phase III study with a 24-week extension period to evaluate the efficacy and safety of dapagliflozin therapy wh...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029505 Non-insulin-dependent diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) HU (Completed) ES (Completed) AT (Completed) SK (Completed) DE (Completed) BG (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000239-28 Sponsor Protocol Number: D1693C00001 Start Date*: 2013-07-15
    Sponsor Name:AstraZeneca AB
    Full Title: DECLARE Dapagliflozin Effect on CardiovascuLAR Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence o...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    19.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) IT (Completed) SE (Completed) SK (Completed) BG (Completed) NL (Completed) ES (Completed) DE (Completed) PL (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004073-31 Sponsor Protocol Number: 2021/1001 Start Date*: 2022-01-17
    Sponsor Name:University Medical Center Groningen
    Full Title: Treating microalbuminuria over 24 weeks in subjects with or without type 2 diabetes or hypertension
    Medical condition: Microalbuminuria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10027525 Microalbuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003310-39 Sponsor Protocol Number: 2021_CHUSTP_DAPAMICRO Start Date*: 2021-10-29
    Sponsor Name:CHU Saint Pierre
    Full Title: Effect of the antidiabetic drug DAPAgliflozin on the coronary macrovascular and MICROvascular function in type 2 diabetic patients (DAPAMICRO)
    Medical condition: Coronary macrovascular and microvascular function of type 2 diabetic patients with stable coronary artery disease and acute coronary syndrome (excluding ST elevation myocardial infarction).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005740-34 Sponsor Protocol Number: ESR-14-10698 Start Date*: 2017-12-08
    Sponsor Name:Universitätsklinikum Tübingen
    Full Title: Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolus insulin treatment (BBIT) regimen to a basal supported oral therapy (BOT) in patients with Type 2 Diabetes – a rando...
    Medical condition: Diabetes Melitus Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005446-15 Sponsor Protocol Number: 202100617 Start Date*: 2022-06-30
    Sponsor Name:University Medical Center Groningen
    Full Title: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Severe Chronic Kidney Disease
    Medical condition: Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002817-78 Sponsor Protocol Number: D5670C00007-Amendment1 Start Date*: 2017-12-06
    Sponsor Name:MedImmune Limited, a wholly owned subsidiary of AstraZeneca
    Full Title: An Exploratory Phase 2a Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of MEDI0382 versus Placebo in Overweight/Obese Subjects with Type 2 Diabetes Mellitus ...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003441-42 Sponsor Protocol Number: D169EC00001 Start Date*: 2019-05-22
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients wi...
    Medical condition: Heart Failure Patients with Preserved Ejection Fraction (HFpEF)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) SK (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004586-41 Sponsor Protocol Number: UOL0753 Start Date*: 2020-06-01
    Sponsor Name:University of Leicester
    Full Title: Impact of exercise training in combination with dapagliflozin on physical function in adults with type 2 diabetes mellitus: A Randomised controlled trial
    Medical condition: Frailty and the preceding 'pre-frail' state in patients with type 2 Diabetes Mellitus.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-004120-11 Sponsor Protocol Number: GN17DI706 Start Date*: 2020-05-05
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide and Dapagliflozin
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-001873-42 Sponsor Protocol Number: D1690R00009 Start Date*: 2015-10-27
    Sponsor Name:University of Liverpool
    Full Title: Pragmatic Randomised 104 Week Multicentre Trial to Evaluate the Comparative Effectiveness of dapagliflozin and Standard of Care in Type 2 Diabetes. The DECIDE Study.
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-000726-10 Sponsor Protocol Number: ADAPT Start Date*: 2021-06-23
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Evaluating the short-term renal and systemic effects of Dapagliflozin in non-diabetic patients with stage IV CKD at risk of ESKD because of severe renal insufficiency and persistent proteinuria: A ...
    Medical condition: Non-diabetic stage IV Chronic Kidney Disease (CKD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004641-25 Sponsor Protocol Number: 201700823 Start Date*: 2019-04-30
    Sponsor Name:University Medical Center Groningen
    Full Title: Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation.
    Medical condition: Proteinuric Kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003721-18 Sponsor Protocol Number: CV181365 Start Date*: 2015-09-14
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial with a Blinded 104-week Long -term Extension Period to Evaluate the Efficacy and Saf...
    Medical condition: Inadequately controlled Diabetes Mellitus Type 2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) HU (Completed) SE (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-005136-41 Sponsor Protocol Number: FIM-DAPA-2018-01 Start Date*: 2018-12-12
    Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud (FIMABIS)
    Full Title: SGLT-2 Inhibition and Cardiovascular Disease. Metabolomics Study of Potential Factors Involved in Cardioprotection
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005042-66 Sponsor Protocol Number: D1680C00019 Start Date*: 2017-11-08
    Sponsor Name:AstraZeneca AB
    Full Title: A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and ...
    Medical condition: Diabetes Mellitus Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-001552-30 Sponsor Protocol Number: PRED-D-TRIAL2015 Start Date*: 2015-10-13
    Sponsor Name:Steno Diabetes Center A/S
    Full Title: Effect of dapagliflozin, metformin and physical activity on glucose variability, body composition and cardiovascular risk in pre-diabetes (The PRE-D Trial) - A randomised, parallel, open-label, int...
    Medical condition: Pre-diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003614-27 Sponsor Protocol Number: GIA-DAP-16-005 Start Date*: 2017-08-16
    Sponsor Name:UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
    Full Title: Study on the effect of dapagliflozin on myocardial insulin sensitivity and perfusion (DapaHeart)
    Medical condition: TYPE 2 DIABETES
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002125-38 Sponsor Protocol Number: DAPA-ESR-16-12460 Start Date*: 2018-11-19
    Sponsor Name:LM Diagnósticos S.L.
    Full Title: Effect of dapagliflozin on nighttime blood pressure in type 2 diabetes
    Medical condition: Patients with diabetes and high blood pressure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005721-25 Sponsor Protocol Number: Lifetime Start Date*: 2023-07-05
    Sponsor Name:Univeristy Hospital Tuebingen
    Full Title: SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial
    Medical condition: The study will include adult male and female patients with an early stage of chronic kidney disease (CKD stage G1A2/G2A2) and prediabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 28 23:46:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA